A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea

NACompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
DiarrheaHIV Infections
Interventions
DRUG

Octreotide

Trial Locations (23)

10029

Mount Sinai Med Ctr, New York

10461

Einstein Med School, The Bronx

19107

Buckley Braffman Stern Med Associates, Philadelphia

22203

Infectious Disease Physicians Inc, Annandale

30303

Emory Univ School of Medicine, Atlanta

33125

Med Service, Miami

48202

Henry Ford Hosp, Detroit

53792

Univ of Wisconsin School of Medicine, Madison

60612

Rush Presbyterian - Saint Luke's Med Ctr, Chicago

64108

Univ of Missouri at Kansas City School of Medicine, Kansas City

77030

Baylor College of Medicine, Houston

77550

Univ TX Galveston Med Branch, Galveston

90033

USC School of Medicine, Los Angeles

92103

UCSD Med Ctr, San Diego

94110

UCSF - San Francisco Gen Hosp, San Francisco

94115

Kaiser Permanente Med Ctr, San Francisco

94403

San Mateo County Gen Hosp, San Mateo

97210

Portland Veterans Adm Med Ctr / Rsch & Education Grp, Portland

117948121

SUNY Stony Brook / Health Sciences Ctr, Stony Brook

04102

Maine Med Ctr Med Clinics, Portland

02115

Douglas Plesko, Boston

02118

Boston City Hosp, Boston

02906

Miriam Hosp / Family Healthcare Ctr at SSTAR, Providence

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sandoz

INDUSTRY

NCT00002252 - A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea | Biotech Hunter | Biotech Hunter